Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT...
NEW YORK, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
View ArticleAegerion Pharmaceuticals Announces Results From First Year of LOWER Study at...
CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
View ArticleHepatitis C cure may cost as low as Rs 67k
NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials...
View ArticleInauguration of the Grifols Chair for the Study of Cirrhosis (Grifols SA)
(Source: Grifols SA) The Grifols Chair for the Study of Cirrhosis, a private chair with an international reach, was created to promote research and education on liver diseases, especially cirrhosis....
View ArticleIntercept Presents New PBC Data at AASLD 2015 (Intercept Pharmaceuticals Inc)
(Source: Intercept Pharmaceuticals Inc) Research Demonstrates Scope of Unmet Need in PBC New Analysis of Phase 3 POISE Study Uses Risk Algorithm to Examine Potential of OCA to Lower Patients' Long-Term...
View Article[www.helio.com] PEG-IFN/ribavirin therapy works equally well at 24 or 48...
(Source: Sun Yat-Sen University) Last updated :2015-12-02 Source:...
View ArticleAbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily...
NORTH CHICAGO, Ill., Dec. 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug...
View ArticleEnanta Pharmaceuticals Announces FDA Acceptance of AbbVie’s New Drug...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
View ArticleAbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Dec. 2, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the...
View ArticleMedicaid Denies Nearly Half Of Requests For Hepatitis C Drugs: Study
People with hepatitis C who sought prescriptions for highly effective but pricey new drugs were significantly more likely to get turned down if they had Medicaid coverage than if they were insured by...
View ArticleEnanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
View ArticleEuropean Medicines Agency Validates Gilead’s Marketing Application for...
(Source: Gilead Sciences Inc) -- If Approved, SOF/VEL Would be the First All-Oral, Pan-Genotypic Single Tablet Regimen for Chronic HCV in Europe -- -- SOF/VEL Granted an Accelerated Assessment by the...
View ArticleMedicaid Denies Nearly Half Of Requests For Hepatitis C Drugs: Study
People with hepatitis C who sought prescriptions for highly effective but pricey new drugs were significantly more likely to get turned down if they had Medicaid coverage than if they were insured by...
View ArticleEnanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
View ArticleNew Results from CLL11 Study Show Gazyva® Provided People with Previously...
(Source: Genentech Inc) / Media Saturday, Dec 5, 2015 South San Francisco, CA -- December 5, 2015 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today updated data...
View ArticleEnanta Pharmaceuticals Announces FDA Acceptance of AbbVie’s New Drug...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
View ArticleCHMP Grants Positive Opinions of AbbVie's VIEKIRAX™...
(Source: AbbVie Inc) NORTH CHICAGO, Ill. , Nov. 21, 2014 /PRNewswire/ -- The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive...
View ArticleAbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of...
NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic,...
View ArticleAbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
(Source: AbbVie Inc) AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 - May 12, 2015 IT STARTS WITH SCIENCE AND ENDS WITH A NEW WAY FORWARD -...
View ArticleOngoing Real World Study Reports High Sustained Viral Response Rates with...
(Source: AbbVie Inc) - Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks...
View Article